Drugs Safety AlertFDA Adds New Safety Warning to ALTUVIIIO Label FDA Adds New Safety Warning to ALTUVIIIO Label Read Post »
Health TidingsGenmab Reports Significant Survival Benefit in LiGeR-HN1 Trial Genmab Reports Significant Survival Benefit in LiGeR-HN1 Trial Read Post »
Clinical TrialsHUTCHMED’s SAFFRON Shows Benefit from Adding Savolitinib After Osimertini... HUTCHMED’s SAFFRON Shows Benefit from Adding Savolitinib After Osimertini... Read Post »
Health Tidings Regulatory & Health PolicyFDA Outlines Single-BLA Framework for Rare Disease Gene Editing FDA Outlines Single-BLA Framework for Rare Disease Gene Editing Read Post »
Clinical TrialsHUTCHMED Reports 24.9-Month PFS With First-Line Savolitinib Combination HUTCHMED Reports 24.9-Month PFS With First-Line Savolitinib Combination Read Post »
Clinical TrialsBioNTech and DualityBio Report Modest PFS Gain but Higher ILD in Breast Can... BioNTech and DualityBio Report Modest PFS Gain but Higher ILD in Breast Can... Read Post »
Health Tidings Mergers & AcquisitionsNovocure to Evaluate TTFields With Verastem’s VS-7375 in Pancreatic Cance... Novocure to Evaluate TTFields With Verastem’s VS-7375 in Pancreatic Cance... Read Post »
Health TidingsAbbVie Submits Etentamig BLA After Response and PFS Gains AbbVie Submits Etentamig BLA After Response and PFS Gains Read Post »
Health TidingsJ&J’s RIPTAC Platform Shows 75% Response in Prostate Cancer J&J’s RIPTAC Platform Shows 75% Response in Prostate Cancer Read Post »
Clinical TrialsPrilenia Reports Functional and Survival Signals for Pridopidine in ALS Prilenia Reports Functional and Survival Signals for Pridopidine in ALS Read Post »
Clinical TrialsUroGen’s Five-Year Data Support Durable JELMYTO Responses UroGen’s Five-Year Data Support Durable JELMYTO Responses Read Post »
Clinical TrialsRetatrutide Delivers 20.9% Mean Weight Loss Against Semaglutide Retatrutide Delivers 20.9% Mean Weight Loss Against Semaglutide Read Post »
Health TidingsOctant Secures FDA Orphan Status for Its Retinitis Pigmentosa Drug Octant Secures FDA Orphan Status for Its Retinitis Pigmentosa Drug Read Post »
Clinical TrialsLynk Reports Positive 76-Week Zemprocitinib Results in Rheumatoid Arthritis Lynk Reports Positive 76-Week Zemprocitinib Results in Rheumatoid Arthritis Read Post »
Health Tidings Mergers & AcquisitionsAstellas and Audax Sign US$1.34 Billion Agreement for DAX-044 Astellas and Audax Sign US$1.34 Billion Agreement for DAX-044 Read Post »
Health TidingsIdorsia Starts Lucerastat Fabry Trial, Secures Nxera Deal Idorsia Starts Lucerastat Fabry Trial, Secures Nxera Deal Read Post »
Clinical TrialsAmgen Reports Phase 3 Success for Dazodalibep in Sjögren’s Disease Amgen Reports Phase 3 Success for Dazodalibep in Sjögren’s Disease Read Post »
Clinical TrialsGrünenthal Reports Sustained Pain Reduction With Qutenza Grünenthal Reports Sustained Pain Reduction With Qutenza Read Post »
Health TidingsFerring Adds Gameto’s Embryo Maturation Technology in Proposed $1.3825B D... Ferring Adds Gameto’s Embryo Maturation Technology in Proposed $1.3825B D... Read Post »
Health TidingsSyncromune Reports 80% Two-Year Survival With SYNC-T Therapy Syncromune Reports 80% Two-Year Survival With SYNC-T Therapy Read Post »
Clinical TrialsVanda Reports Positive Results for Tradipitant in GLP-1 Vomiting Vanda Reports Positive Results for Tradipitant in GLP-1 Vomiting Read Post »
Clinical TrialsBeam’s BEAM-301 Shows Early Metabolic Benefits in GSDIa Beam’s BEAM-301 Shows Early Metabolic Benefits in GSDIa Read Post »
Clinical TrialsArtiva Ends AlloNK Development After Durability Shortfall and Two Fatal Eve... Artiva Ends AlloNK Development After Durability Shortfall and Two Fatal Eve... Read Post »
Clinical TrialsPfizer Reports Positive PFS Results for ELREXFIO in RRMM Trial Pfizer Reports Positive PFS Results for ELREXFIO in RRMM Trial Read Post »
Clinical TrialsOncolytics Reports Promising Survival Data With Pelareorep Combination Oncolytics Reports Promising Survival Data With Pelareorep Combination Read Post »
Health Tidings Mergers & AcquisitionsTeva Acquires BXCL501, Targeting At-Home Agitation Care Teva Acquires BXCL501, Targeting At-Home Agitation Care Read Post »
Health Tidings Mergers & AcquisitionsRumi Advances PDE2 Inhibitor RTX-7340 for Fragile X Syndrome Rumi Advances PDE2 Inhibitor RTX-7340 for Fragile X Syndrome Read Post »
Clinical TrialsTonix Reports Positive FIQR Results for TONMYA in Fibromyalgia Trials Tonix Reports Positive FIQR Results for TONMYA in Fibromyalgia Trials Read Post »
Health TidingsBoehringer Ingelheim and AimedBio Advance BI 4060107 Into Cancer Trial Boehringer Ingelheim and AimedBio Advance BI 4060107 Into Cancer Trial Read Post »
Health TidingsInsilico’s AI-Designed ISM6331 Shows Tumor Shrinkage in Mesothelioma Insilico’s AI-Designed ISM6331 Shows Tumor Shrinkage in Mesothelioma Read Post »
Health TidingsGSK’s Ris-Rez Cuts Progression Risk by 67% in Osteosarcoma Trial GSK’s Ris-Rez Cuts Progression Risk by 67% in Osteosarcoma Trial Read Post »
Clinical TrialsHenlius Reports Longer Overall Survival With Serplulimab in ES-SCLC Henlius Reports Longer Overall Survival With Serplulimab in ES-SCLC Read Post »
Clinical TrialsMerck KGaA Reports Durable Tumor Control With Pimicotinib at Two Years Merck KGaA Reports Durable Tumor Control With Pimicotinib at Two Years Read Post »
New Drug ApprovalAstraZeneca’s Enhertu Wins EU Approval in Early Breast Cancer AstraZeneca’s Enhertu Wins EU Approval in Early Breast Cancer Read Post »
Health TidingsMerck’s Keytruda Outperforms Chemotherapy on PFS in dMMR Cancer Merck’s Keytruda Outperforms Chemotherapy on PFS in dMMR Cancer Read Post »
Health TidingsMerck’s Sac-TMT Cuts Death Risk by 32% in Endometrial Cancer Merck’s Sac-TMT Cuts Death Risk by 32% in Endometrial Cancer Read Post »
Clinical TrialsIambic’s IAM1363 Shows Early Activity Against Brain Metastases Iambic’s IAM1363 Shows Early Activity Against Brain Metastases Read Post »
New Drug ApprovalFDA Approves Pfizer’s TALZENNA Plus XTANDI for HRR-Mutated mHSPC FDA Approves Pfizer’s TALZENNA Plus XTANDI for HRR-Mutated mHSPC Read Post »
Clinical TrialsIncyte Reports Strong Responses with KRAS G12D and TGFβR2×PD-1 Therapies Incyte Reports Strong Responses with KRAS G12D and TGFβR2×PD-1 Therapies Read Post »
Clinical TrialsMirum Reports Positive Zilurgisertib Results in Children With FOP Mirum Reports Positive Zilurgisertib Results in Children With FOP Read Post »
Health TidingsLilly Reports Promising Results for Olomorasib in Lung Cancer Lilly Reports Promising Results for Olomorasib in Lung Cancer Read Post »
Health TidingsLongeveron Reports Fewer Cardiac Events in Infants With HLHS Longeveron Reports Fewer Cardiac Events in Infants With HLHS Read Post »
Health TidingsEledon’s Tegoprubart Outperforms Tacrolimus on Quality of Life After Kidn... Eledon’s Tegoprubart Outperforms Tacrolimus on Quality of Life After Kidn... Read Post »
Clinical TrialsCorcept Reports Positive BELLA Results for Lifyorli Triplet Corcept Reports Positive BELLA Results for Lifyorli Triplet Read Post »
Health Tidings Mergers & AcquisitionsIncyte, Genmab Partner on KRAS G12D Colorectal Cancer Trial Incyte, Genmab Partner on KRAS G12D Colorectal Cancer Trial Read Post »
Clinical TrialsJ&J Reports 62% EFS Risk Reduction With ERLEADA Plus ADT J&J Reports 62% EFS Risk Reduction With ERLEADA Plus ADT Read Post »
Clinical TrialsAgenus Reports 72% Complete Response with BOT+BAL in dMMR Colon Cancer Agenus Reports 72% Complete Response with BOT+BAL in dMMR Colon Cancer Read Post »
Health TidingsBayer’s Darolutamide Improves Four-Year Metastasis-Free Survival to 95% Bayer’s Darolutamide Improves Four-Year Metastasis-Free Survival to 95% Read Post »
Clinical TrialsAstraZeneca’s Sonesitatug Vedotin Meets OS but Misses PFS Endpoint AstraZeneca’s Sonesitatug Vedotin Meets OS but Misses PFS Endpoint Read Post »
Clinical TrialsJ&J Reports Strong Tumour Responses With RYBREVANT FASPRO J&J Reports Strong Tumour Responses With RYBREVANT FASPRO Read Post »
Health TidingsSystImmune Reports Higher Response Rates With Izalontamab Brengitecan in NS... SystImmune Reports Higher Response Rates With Izalontamab Brengitecan in NS... Read Post »
